Ayurvedic Management of Rheumatoid Arthritis.

Randomised Control Trial of Ajmodadi Watak with Vaitarana Basti in Amavata with special reference to Rheumatoid Arthritis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031029

Enrollment

Registered

2021-02-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: To study effect of Ajmodadi Watak along with Vaitarana Basti.: Ajmodadi Watak 250mg 2 BD Route -Orally Control Intervention1: To study effect of Devdarvyadi Ghanavati along with Vaitara

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients willing and able to participate in study. 2) Patients who have not participated in any other research project since last 6 months. 3) Patients presenting signs and symptoms of Amavata as mentioned in classics. 4)All patients fulfilling American Criteria of Rheumatoid Arthritis (2010). 5) Patients of either sex aged between 20-70 years. 6) Patients of Amavata having chronicity 7) Patients of Rheumatoid Arthritis having controlled hypertension and diabetes. 8)If any patient is on corticosteroids or any other drug then thesis drug will start after tapering and withdrawal of drug.

Exclusion criteria

Exclusion criteria: 1) Patients not willing for trial. 2) Patients having gross disability in performing daily normal routine i.e bedridden patients or confined to wheelchair. 3) Patients with comorbidities such as Gouty Arthritis,Syphilitic Arthritis etc 4) Patients with poorly controlled Hypertension ( >160/100 mmHg) 5) Patients with poorly controlled Diabetes Mallitus(BSL fasting >130 mg/do,Post Prandial >250mg/dl) 6) Patients with evidence of maliganacy. 7) Patients who currently participated in any other clinical trial. 8) Patients contraindicated for Basti as mentioned in Samhitas. 9)Any other condition which researcher think may jeopardize the study. 10) Pregnant or lactating females.

Design outcomes

Primary

Measure	Time frame
To evaluate effect of oral administration of Ajmodadi Watak with Vaitarana Basti in Management of Amavata.Timepoint: 35 days	—

Secondary

Measure	Time frame
To compare effect of oral administration of Ajmodadi Watak with Vaitarana Basti with effect of oral administration of Devdarvyadi Ghanavati along with Vaitarana Basti in Management of AmavataTimepoint: 35 days	—

Countries

India

Contacts

Public ContactPooja Suresh Umate

Government Ayurveda College Nagpur

Sushilvilaschawre@gmail.com9923755771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026